Providing patients with chronic pain treatment options while deterring the potential for prescription abuse is our primary pursuit. Employing our proprietary Guardian™ Technology, we are developing a number of exciting therapies designed to address the issue of abuse while delivering effective analgesia.
| Product | Indication | Phase | Commercialization |
|---|---|---|---|
| OXAYDO™ (AD IR oxycodone) | Acute and chronic moderate to severe pain | Approved | Egalet to market |
| SPRIX® (ketorolac tromethamine) | Short-term (up to 5 days) management of moderate to moderately severe pain | Approved | Egalet to market |
| Egalet-001 (AD ER morphine) | Chronic pain* | Phase 3 to enroll Q1:15 | Egalet to market |
| Egalet-002 (AD ER oxycodone) | Chronic pain* | Pivotal trials to start Q1:15 | Egalet to market |
| Egalet-003 | TBD | Preclinical | Egalet to market |
| AD ER hydrocodone | Chronic pain* | Preclinical | Shionogi to market |
AD = abuse-deterrent; ER = extended release.
*Management of pain severe enough to require around-the-clock opioid treatment and for which alternative treatments are inadequate.
Guardian Technology is a trademark of Egalet Corporation.